Pharmaceutical aspects of oligonucleotides:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
London
Taylor & Francis
2000
|
| Ausgabe: | 1. publ. |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIII, 321 S. Ill., graph. Darst. |
| ISBN: | 074840841X |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV013073276 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 000329s2000 ad|| |||| 00||| eng d | ||
| 020 | |a 074840841X |9 0-748-40841-X | ||
| 035 | |a (OCoLC)41482500 | ||
| 035 | |a (DE-599)BVBBV013073276 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 | ||
| 050 | 0 | |a RM666.N87 | |
| 082 | 0 | |a 615/.31 |2 21 | |
| 245 | 1 | 0 | |a Pharmaceutical aspects of oligonucleotides |c ed. by Patrick Couvreur ... |
| 250 | |a 1. publ. | ||
| 264 | 1 | |a London |b Taylor & Francis |c 2000 | |
| 300 | |a XIII, 321 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 7 | |a Acides nucléiques antisens - Emploi en thérapeutique |2 ram | |
| 650 | 7 | |a Anwendung |2 swd | |
| 650 | 7 | |a Farmacologie |2 gtt | |
| 650 | 7 | |a Oligonucleotide |2 swd | |
| 650 | 7 | |a Oligonucleotiden |2 gtt | |
| 650 | 2 | |a Oligonucléotides - effets indésirables | |
| 650 | 2 | |a Oligonucléotides - usage thérapeutique | |
| 650 | 7 | |a Therapie |2 swd | |
| 650 | 7 | |a Vecteurs de médicaments |2 ram | |
| 650 | 4 | |a Oligonucleotides |x Therapeutic use | |
| 650 | 4 | |a Oligonucleotides |x adverse effects | |
| 650 | 4 | |a Oligonucleotides |x therapeutic use | |
| 700 | 1 | |a Couvreur, Patrick |e Sonstige |4 oth | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008907526&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-008907526 | ||
Datensatz im Suchindex
| _version_ | 1804127771633385472 |
|---|---|
| adam_text | O PHARMACEUTICAL ASPECTS OF OLIGONUCLEOTIDES EDITED BY PATRICK COUVREUR
UNIVERSITY OF PARIS-SUD CNRS UNIT PHYSICO-CHIMIE, PHARMACOTECHNIE,
BIOPHARMACIE , CHATENAY-MALABRY, FRANCE CLAUDE MALVY CNRS, INSTITUT G.
ROUSSY, VILLEJUIF, FRANCE CONTENTS CONTRIBUTORS PAGE X PREFACE XII PART
ONE GENERAL FEATURES 1 1 MECHANISMS OF ACTION OF ANTISENSE
OLIGONUCLEOTIDES 3 D.M. TIDD AND R.V. GILES 1.1 INTRODUCTION 3 1.2 CELL
PROLIFERATION ARREST THROUGH RELEASE OF DEOXYNUCLEOSIDES 4 1.3
EXTRACELLULAR APTAMERIC EFFECTS OF PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDE
ANALOGUES 6 1.4 APTAMERIC EFFECTS OF G-QUARTET OLIGONUCLEOTIDES AND
ANALOGUES 7 1.5 IMMUNE STIMULATION BY OLIGODEOXYNUCLEOTIDES CONTAINING
CPG MOTIFS 10 1.6 OTHER ACTIVITIES OF OLIGODEOXYNUCLEOTIDES CONTAINING
CPG MOTIFS 11 1.7 ANTISENSE INHIBITION OF GENE EXPRESSION BY STERIC
BLOCK 12 1.8 ANTISENSE INHIBITION OF GENE EXPRESSION THROUGH
RIBONUCLEASE H-MEDIATED DESTRUCTION OF TARGET MRNA 14 1.9
OLIGONUCLEOTIDES IN VIVO 21 1.10 CONCLUSIONS 21 ACKNOWLEDGEMENTS 22
REFERENCES 22 PART TWO CHEMICAL ASPECTS 33 2 CHEMISTRY OF
OLIGONUCLEOTIDES 35 J.W. ENGELS AND E. UHLMANN 2.1 INTRODUCTION 35 2.2
DESIGN OF OLIGONUCLEOTIDES 39 VI CONTENTS 2.3 OLIGONUCLEOTIDE
MODIFICATIONS: SYNTHESIS AND PROPERTIES 42 2.4 ANALYSIS OF
OLIGONUCLEOTIDES 59 2.5 CONCLUSION 68 ACKNOWLEDGEMENT 68 REFERENCES 68 3
THE OLIGONUCLEOTIDE PRODRUG APPROACH: THE PRO-OLIGONUCLEOTIDES 79 F.
MORVAN, J.-J. VASSEUR, E. VIVES, B. RAYNER AND J.-L. IMBACH 3.1
INTRODUCTION 79 3.2 WHAT KIND OF ENZYMOLABILE GROUP? 80 3.3 FIRST
PRO-OLIGONUCLEOTIDE MODELS 83 3.4 PRO-OLIGONUCLEOTIDES OF THE SECOND
GENERATION 86 3.5 CONCLUSION 92 ACKNOWLEDGEMENTS 94 REFERENCES 94 4
PEPTIDE NUCLEIC ACIDS 98 P.E. NIELSEN 4.1 INTRODUCTION 98 4.2 ANTISENSE
99 4.3 ANTIMICROBIALS 101 4.4 ANTI-TELOMERASE 101 4.5 ANTIGENE 101 4.6
ANTI-HIV 103 4.7 PHARMACOLOGY 103 4.8 FURTHER DEVELOPMENTS 103
ACKNOWLEDGEMENT 104 REFERENCES 104 PART THREE DELIVERY 109 5
PEPTIDE-MEDIATED DELIVERY OF OLIGONUCLEOTIDES 111 E. VIVES AND B. LEBLEU
5.1 DELIVERY VEHICLES FOR THE IMPROVED UPTAKE OF NUCLEIC ACIDS: A SURVEY
111 5.2 THE POTENTIAL OF PEPTIDES FOR NUCLEIC ACIDS DELIVERY 112 5.3
STRATEGIES FOR THE COUPLING OF PEPTIDES TO OLIGONUCLEOTIDES 114 5.4 POLY
(L-LYSINE)-BASED DELIVERY SYSTEMS 116 5.5 CONJUGATION TO FUSOGENIC
PEPTIDES ALLOWING MEMBRANE FUSION OR MEMBRANE TRANSLOCATION 117 5.6
CONCLUSIONS 123 ACKNOWLEDGEMENTS 123 REFERENCES 123 CONTENTS VII 6
POLYMERIC NANOPARTICLES AND MICROPARTICLES AS CARRIERS FOR ANTISENSE
OLIGONUCLEOTIDES 128 E. FATTAL AND P. COUVREUR 6.1 INTRODUCTION 128 6.2
NANOPARTICLES 129 6.3 IN VITRO STABILITY OF ONS ADSORBED ONTO
NANOPARTICLES 137 6.4 CELL INTERACTIONS WITH ON LOADED NANOPARTICLES 138
6.5 IN VITRO PHARMACOLOGICAL ACTIVITY OF OLIGONUCLEOTIDE-LOADED
NANOPARTICLES 138 6.6 IN VIVO STUDIES WITH OLIGONUCLEOTIDE NANOPARTICLES
139 6.7 MICROPARTICLES 140 6.8 CONCLUSION 140 REFERENCES 141 7 LIPOSOMES
FOR THE DELIVERY OF OLIGONUCLEOTIDES 146 P. COUVREUR, C. MALVY, C.
DUBERNET AND E. FATTAL 7.1 INTRODUCTION 146 7.2 ANIONIC LIPOSOMES 147
7.3 CATIONIC LIPOSOMES 150 7.4 PH-SENSITIVE LIPOSOMES 157 7.5
IMMUNOLIPOSOMES AND OTHER MOLECULARLY TARGETED LIPOSOMES 160 7.6
FUSOGENIC LIPOSOMES AND PROTEOLIPOSOMES 163 7.7 CONCLUSIONS 164
REFERENCES 165 8 COMB-TYPE POLYCATION COPOLYMER FOR ANTIGENE STRATEGY
AND DNA CARRIER 172 A. MARUYAMA 8.1 INTRODUCTION 172 8.2 COMB-TYPE
POLYCATIONS AS A STABILIZER FOR DNA DUPLEX AND TRIPLEX 172 8.3 COMB-TYPE
POLYCATION COPOLYMERS WITH CELL-SPECIFIC POLYSACCHARIDE SIDE-CHAINS AS
CELL-SPECIFIC DNA CARRIER 184 ACKNOWLEDGEMENTS 192 REFERENCES 192 PART
FOUR BIOPHARMACEUTICS 199 9 DELIVERY OF ANTISENSE OLIGONUCLEOTIDES IN
VITRO: EXPERIMENTAL POINTS 201 G.B. TAKLE AND C.A. STEIN 9.1
INTRODUCTION 201 9.2 OLIGONUCLEOTIDE-BINDING PROTEINS ON THE CELL
SURFACE 203 VIII CONTENTS 9.3 INTRACELLULAR COMPARTMENTALIZATION 205 9.4
OLIGONUCLEOTIDE DELIVERY REAGENTS - PRACTICAL CONSIDERATIONS 206 9.5
EXPERIMENTAL ANTISENSE: POINTS TO CONSIDER 207 REFERENCES 210 10
MECHANISMS OF TRANSMEMBRANE TRANSPORT OF OLIGONUCLEOTIDES 213 R.L.
JULIANO 10.1 OVERVIEW OF CELLULAR UPTAKE OF ANTISENSE OLIGONUCLEOTIDES
213 10.2 PERMEATION OF OLIGONUCLEOTIDES ACROSS MEMBRANES 215 10.3
MECHANISMS OF ENHANCEMENT OF OLIGONUCLEOTIDE PERMEATION ACROSS MEMBRANES
217 10.4 SUMMARY 220 REFERENCES 221 11 PHARMACOKINETICS OF
OLIGODEOXYNUCLEOTIDES 226 A. GOUYETTE 11.1 INTRODUCTION 226 11.2
PHARMACOKINETICS 227 11.3 CHEMISTRY OF OLIGONUCLEOTIDES AND FORMULATIONS
229 11.4 CELLULAR PHARMACOKINETICS 229 11.5 PRECLINICAL PHARMACOKINETICS
230 11.6 CLINICAL PHARMACOKINETICS 234 11.7 CONCLUSIONS 236 REFERENCES
236 PART FIVE PHARMACOLOGICAL ACTIVITY 241 12 ANTISENSE AS A NOVEL
THERAPY FOR CANCER 243 B.P. MONIA 12.1 NOVEL APPROACHES FOR ANTICANCER
THERAPY 243 12.2 ANTISENSE APPROACHES FOR CANCER 245 12.3 ANTISENSE AS A
NOVEL ANTICANCER APPROACH AGAINST RAS 250 12.4 CONCLUSIONS AND FUTURE
PROSPECTS 259 ACKNOWLEDGEMENTS 259 REFERENCES 260 13 MODULATION OF
INFLAMMATORY PROCESSES WITH ANTISENSE OLIGONUCLEOTIDES 263 C.F. BENNETT
13.1 INTRODUCTION 263 13.2 ICAM-1, A CASE STUDY 264 13.3 OTHER EXAMPLES
275 CONTENTS IX 13.4 REGULATION OF IMMUNE RESPONSE BY NON-ANTISENSE
MECHANISMS 278 13.5 CONCLUSIONS _ 279 REFERENCES 280 14 OLIGONUCLEOTIDES
AS ANTIPARASITE COMPOUNDS 286 J.-J. TOULME 14.1 INTRODUCTION 286 14.2
DESIGN OF ANTISENSE OLIGONUCLEOTIDES FOR ANTIPARASITE USE 287 14.3
ANTIPARASITE EFFECTS OF ANTISENSE OLIGONUCLEOTIDES 290 14.4 RNA
STRUCTURES ARE VALID TARGETS FOR REGULATORY OLIGONUCLEOTIDES 297 14.5
CONCLUSION 302 ACKNOWLEDGEMENTS 303 REFERENCES 304 INDEX 309
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV013073276 |
| callnumber-first | R - Medicine |
| callnumber-label | RM666 |
| callnumber-raw | RM666.N87 |
| callnumber-search | RM666.N87 |
| callnumber-sort | RM 3666 N87 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| ctrlnum | (OCoLC)41482500 (DE-599)BVBBV013073276 |
| dewey-full | 615/.31 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.31 |
| dewey-search | 615/.31 |
| dewey-sort | 3615 231 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 1. publ. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01613nam a2200445 c 4500</leader><controlfield tag="001">BV013073276</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">000329s2000 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">074840841X</subfield><subfield code="9">0-748-40841-X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)41482500</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV013073276</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM666.N87</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.31</subfield><subfield code="2">21</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmaceutical aspects of oligonucleotides</subfield><subfield code="c">ed. by Patrick Couvreur ...</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. publ.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London</subfield><subfield code="b">Taylor & Francis</subfield><subfield code="c">2000</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIII, 321 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Acides nucléiques antisens - Emploi en thérapeutique</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anwendung</subfield><subfield code="2">swd</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Farmacologie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oligonucleotide</subfield><subfield code="2">swd</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oligonucleotiden</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Oligonucléotides - effets indésirables</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Oligonucléotides - usage thérapeutique</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Therapie</subfield><subfield code="2">swd</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vecteurs de médicaments</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oligonucleotides</subfield><subfield code="x">Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oligonucleotides</subfield><subfield code="x">adverse effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oligonucleotides</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Couvreur, Patrick</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008907526&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-008907526</subfield></datafield></record></collection> |
| id | DE-604.BV013073276 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T18:38:39Z |
| institution | BVB |
| isbn | 074840841X |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-008907526 |
| oclc_num | 41482500 |
| open_access_boolean | |
| owner | DE-12 |
| owner_facet | DE-12 |
| physical | XIII, 321 S. Ill., graph. Darst. |
| publishDate | 2000 |
| publishDateSearch | 2000 |
| publishDateSort | 2000 |
| publisher | Taylor & Francis |
| record_format | marc |
| spelling | Pharmaceutical aspects of oligonucleotides ed. by Patrick Couvreur ... 1. publ. London Taylor & Francis 2000 XIII, 321 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Acides nucléiques antisens - Emploi en thérapeutique ram Anwendung swd Farmacologie gtt Oligonucleotide swd Oligonucleotiden gtt Oligonucléotides - effets indésirables Oligonucléotides - usage thérapeutique Therapie swd Vecteurs de médicaments ram Oligonucleotides Therapeutic use Oligonucleotides adverse effects Oligonucleotides therapeutic use Couvreur, Patrick Sonstige oth GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008907526&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Pharmaceutical aspects of oligonucleotides Acides nucléiques antisens - Emploi en thérapeutique ram Anwendung swd Farmacologie gtt Oligonucleotide swd Oligonucleotiden gtt Oligonucléotides - effets indésirables Oligonucléotides - usage thérapeutique Therapie swd Vecteurs de médicaments ram Oligonucleotides Therapeutic use Oligonucleotides adverse effects Oligonucleotides therapeutic use |
| title | Pharmaceutical aspects of oligonucleotides |
| title_auth | Pharmaceutical aspects of oligonucleotides |
| title_exact_search | Pharmaceutical aspects of oligonucleotides |
| title_full | Pharmaceutical aspects of oligonucleotides ed. by Patrick Couvreur ... |
| title_fullStr | Pharmaceutical aspects of oligonucleotides ed. by Patrick Couvreur ... |
| title_full_unstemmed | Pharmaceutical aspects of oligonucleotides ed. by Patrick Couvreur ... |
| title_short | Pharmaceutical aspects of oligonucleotides |
| title_sort | pharmaceutical aspects of oligonucleotides |
| topic | Acides nucléiques antisens - Emploi en thérapeutique ram Anwendung swd Farmacologie gtt Oligonucleotide swd Oligonucleotiden gtt Oligonucléotides - effets indésirables Oligonucléotides - usage thérapeutique Therapie swd Vecteurs de médicaments ram Oligonucleotides Therapeutic use Oligonucleotides adverse effects Oligonucleotides therapeutic use |
| topic_facet | Acides nucléiques antisens - Emploi en thérapeutique Anwendung Farmacologie Oligonucleotide Oligonucleotiden Oligonucléotides - effets indésirables Oligonucléotides - usage thérapeutique Therapie Vecteurs de médicaments Oligonucleotides Therapeutic use Oligonucleotides adverse effects Oligonucleotides therapeutic use |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=008907526&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT couvreurpatrick pharmaceuticalaspectsofoligonucleotides |